Moderna, Inc. (MRNA)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Moderna, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Moderna, Inc. (MRNA) has returned 72.26% so far this year and 79.19% over the past 12 months.

Based on dividend-adjusted daily data since Dec 7, 2018, MRNA's average daily return is +0.16%, while the average monthly return is +3.52%. At this rate, your investment would double in approximately 1.7 years.

Historically, 52% of months were positive and 48% were negative. The best month was Nov 2020 with a return of +126.4%, while the worst month was Aug 2024 at -35.1%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 8 months.

On a daily basis, MRNA closed higher 48% of trading days. The best single day was Feb 25, 2020 with a return of +27.8%, while the worst single day was Aug 1, 2024 at -21.0%.

Moderna, Inc. has an annualized alpha of 33.08%, beta of 0.76, and R² of 0.04 versus S&P 500 Index. Calculated based on daily prices since December 10, 2018.

• This stock captured 102.01% of S&P 500 Index gains but only 96.32% of its losses — a favorable profile for investors.
• R² of 0.04 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

MRNA ranks 74 for risk / return — better than 74% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Moderna, Inc. (MRNA) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Moderna, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Moderna, Inc. was 95.38%, occurring on Nov 20, 2025. The portfolio has not yet recovered.

The current Moderna, Inc. drawdown is 89.51%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Moderna, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Moderna, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.